Serotonin 5-HT2A Receptor Activation Blocks TNF-α Mediated Inflammation In Vivo

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Nau Jr , Felix ^a   Yu, Bangning ^a   Martin, David ^a   Nichols, Charles D ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; FRACTALKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VOLINANSERIN; ANTIINFLAMMATORY AGENT; SEROTONIN 2 AGONIST; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA ARCH; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG POTENCY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SMALL INTESTINE; ANIMAL; C57BL MOUSE; DRUG EFFECT; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; INFLAMMATION; INTESTINE, SMALL; MALE; MICE; MICE, INBRED C57BL; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884862354     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075426     Document Type: Article

References (37)

1. Nichols DE, Nichols CD, (2008) Serotonin receptors. Chem Rev 108: 1614-1641 doi:10.1021/cr078224o.
2. Meneses A, (1999) 5-HT system and cognition. Neurosci Biobehav Rev 23: 1111-1125.
3. Villalon CM, Centurion D, (2007) Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedebergs Arch Pharmacol 376: 45-63.
4. Watts SW, Davis RP (2010) 5-Hydroxtryptamine Receptors in Systemic Hypertension: An Arterial Focus. Cardiovascular therapeutics. doi:10.1111/j.1755-5922.2010.00173.x.
5. Sanger G, (2008) 5-Hydroxytryptamine and the gastrointestinal tract: where next? Trends in Pharmacological Sciences 29: 465-471 doi:10.1016/j.tips.2008.06.008.
6. Ahern GP, (2011) 5-HT and the immune system. Current Opinion in Pharmacology 11: 29-33.
7. Mossner R, Lesch KP, (1998) Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 12: 249-271 doi:10.1006/brbi.1998.0532.
8. Kubera M, Maes M, Kenis G, Kim Y, Lason W, (2005) Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 134: 251-258.
9. Stefulj J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K, (2000) mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun 14: 219-224 doi:10.1006/brbi.1999.0579.
10. Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, et al. (2008) Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 327: 316-323 doi:10.1124/jpet.108.143461.
11. Henninger DD, Panés J, Eppihimer M, Russell J, Gerritsen M, et al. (1997) Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 158: 1825-1832.
12. Hummon AB, Lim SR, Difilippantonio MJ, Ried T, (2007) Isolation and solubilization of proteins after TRIzol extraction of RNA and DNA from patient material following prolonged storage. BioTechniques 42: 467-70-472.
13. Smith R, Barrett R, Sanders-Bush E, (2003) Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice. Psychopharmacology (Berl) 166: 61-68.
14. Schmid CL, Raehal KM, Bohn LM, (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105: 1079-1084 doi:10.1073/pnas.0708862105.
15. Fox MA, French HT, LaPorte JL, Blackler AR, Murphy DL, (2010) The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis. Psychopharmacology (Berl) 212: 13-23 doi:10.1007/s00213-009-1694-1.
16. Canal CE, Morgan D, (2012) Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Analysis 4: 556-576 doi:10.1002/dta.1333.
17. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, et al. (1994) Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331: 1474-1479 doi:10.1056/NEJM199412013312202.
18. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126 doi:10.1056/NEJM199901143400207.
19. Parameswaran N, Patial S, (2010) Tumor Necrosis Factor-α Signaling in Macrophages. Critical reviews in eukaryotic gene expression 20: 87.
20. Lusis AJ, (2000) Atherosclerosis. Nature 407: 233-241 doi:10.1038/35025203.
21. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, et al. (2003) Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 23: 656-660 doi:10.1161/01.ATV.0000064374.15232.C3.
22. Gershon MD, (2001) Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Alimentary Pharmacology & Therapeutics 13: 15-30 doi:10.1046/j.1365-2036.1999.00002.x-i2.
23. Neal KB, Parry LJ, Bornstein JC, (2009) Strain-specific genetics, anatomy and function of enteric neural serotonergic pathways in inbred mice. The Journal of Physiology 587: 567-586 doi:10.1113/jphysiol.2008.167676.
24. Crowell MD, (2004) Role of serotonin in the pathophysiology of the irritable bowel syndrome. British Journal of Pharmacology 141: 1285-1293 doi:10.1038/sj.bjp.0705762.
25. Spiller R, (2007) Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 19Suppl 2: 25-31 doi:10.1111/j.1365-2982.2007.00965.x.
26. Garvin B, Wiley JW, (2008) The role of serotonin in irritable bowel syndrome: Implications for management. Curr Gastroenterol Rep 10: 363-368 doi:10.1007/s11894-008-0070-3.
27. Spiller R, (2008) Serotonin and GI clinical disorders. Neuropharmacology 55: 1072-1080 doi:10.1016/j.neuropharm.2008.07.016.
28. Markoutsaki T, Karantanos T, Gazouli M, Anagnou NP, Karamanolis DG (2011) 5-HT2A Receptor Gene Polymorphisms and Irritable Bowel Syndrome. J Clin Gastroenterol. doi:10.1097/MCG.0b013e318205e13b.
29. Bradley J, (2008) TNF-mediated inflammatory disease. J Pathol 214: 149-160 doi:10.1002/path.2287.
30. Lee TW, Fedorak RN, (2010) Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. Gastroenterology Clinics of North America 39: 543-557 doi:10.1016/j.gtc.2010.08.018.
31. Ngo B, Farrell CP, Barr M, Wolov K, Bailey R, et al. (2010) Tumor necrosis factor blockade for treatment of in. Curr Mol Pharmacol. 3: 145-152.
32. Gershon MD, (2012) Serotonin is a Sword and a Shield of the Bowel: Serotonin Plays Offense and Defense. Transactions of the American Clinical and Climatological Association 123: 268.
33. Nishiyama T, (2009) Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats. Eur J Pharmacol 614: 122-127 doi:10.1016/j.ejphar.2009.03.041.
34. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, et al. (2006) Functional Selectivity and Classical Concepts of Quantitative Pharmacology. J Pharmacol Exp Ther 320: 1-13 doi:10.1124/jpet.106.104463.
35. Kenakin T, Miller LJ, (2010) Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery. Pharmacological Reviews 62: 265-304 doi:10.1124/pr.108.000992.
36. Furrera K, Rickenbachera A, Tiana Y, Jochumb W, Bittermannc AG, et al. (2011) Serotonin reverts age-related capillarization andfailure of regeneration in the liver through a VEGF-dependent pathway. PNAS 108: 2945-2950 doi:-? = = 10.1073/pnas.1012531108/-/DCSupplemental/pnas.201012531SI.pdf?targetid = nameddest = SF1.
37. Comet M, Bernard J, Hamon M, Laguzzi R, Sevoz-Couche C, (2007) Activation of nucleus tractus solitarius 5-HT2A but not other 5-HT2 receptor subtypes inhibits the sympathetic activity in rats. Eur J Neurosci 26: 345-354.